Evidence map›Paper›PMID 34888240›Full record

ArticleFrontiers in oncology2021

An Early-Onset Advanced Rectal Cancer Patient With Increased KRAS Gene Copy Number Showed A Primary Resistance to Cetuximab in Combination With Chemotherapy: A Case Report.

Tian Fang, Tingting Liang, Yizhuo Wang, Haitao Wu, Shuhan Liu, Linying Xie, Zhihao Zhang, Jiaying Liang, Cheng Yao, Yehui Tan and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tian FangCancer Center, The First Hospital of Jilin University, Changchun, China.
Tingting LiangCancer Center, The First Hospital of Jilin University, Changchun, China.
Yizhuo WangCancer Center, The First Hospital of Jilin University, Changchun, China.
Haitao WuCancer Center, The First Hospital of Jilin University, Changchun, China.
Shuhan LiuCancer Center, The First Hospital of Jilin University, Changchun, China.
Linying XieBethune Institute of Epigenetic Medicine, The First Hospital of Jilin University, Changchun, China.
Zhihao ZhangDepartment of Breast Surgery, The First Hospital of Jilin University, Changchun, China.
Jiaying LiangCancer Center, The First Hospital of Jilin University, Changchun, China.
Cheng YaoCancer Center, The First Hospital of Jilin University, Changchun, China.
Yehui TanCancer Center, The First Hospital of Jilin University, Changchun, China.
Chang WangCancer Center, The First Hospital of Jilin University, Changchun, China.
First Hospital of Jilin University · CNJilin University · CNFirst Bethune Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in

Indexed as

anti-EGFR monoclonal antibodycase reportcetuximabcolorectal cancergene amplificationgene copy numberKRAS

Identifiers

PMID34888240
PMCPMC8649836
OpenAlexW3215250438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.